These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19517310)

  • 1. American Association for Cancer Research--100th Annual Meeting. HDAC inhibitors, proteasome inhibitors and vascular disrupting agents. 18-22 April 2009, Denver, CO, USA.
    Mitra AP
    IDrugs; 2009 Jun; 12(6):339-41. PubMed ID: 19517310
    [No Abstract]   [Full Text] [Related]  

  • 2. American Association for Cancer Research--100th Annual Meeting. New therapeutic developments: part 2. 18-22 April 2009, Denver, CO, USA.
    Gale S; McGee V; Lee W
    IDrugs; 2009 Jun; 12(6):335-8. PubMed ID: 19517309
    [No Abstract]   [Full Text] [Related]  

  • 3. American Association for Cancer Research--100th Annual Meeting. New therapeutic developments: part 1. 18-22 April 2009, Denver, CO, USA.
    Gale S; McGee V; Lee W
    IDrugs; 2009 Jun; 12(6):331-4. PubMed ID: 19517308
    [No Abstract]   [Full Text] [Related]  

  • 4. American Association for Cancer Research 98th Annual Meeting. Anticancer agents - Part I.
    Kneller S
    IDrugs; 2007 Jun; 10(6):356-8. PubMed ID: 17641993
    [No Abstract]   [Full Text] [Related]  

  • 5. HDAC Inhibitors--CHI's Third Annual Conference.
    Rosato RR
    IDrugs; 2010 Jan; 13(1):13-5. PubMed ID: 20024840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference.
    Marblestone JG
    IDrugs; 2009 Dec; 12(12):750-3. PubMed ID: 19943215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Carew JS; Giles FJ; Nawrocki ST
    Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphatases as targets for cancer treatment.
    Lazo JS; Wipf P
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1297-304. PubMed ID: 19943201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
    Watanabe T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1113-27. PubMed ID: 20649502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.
    Riester D; Hildmann C; Schwienhorst A
    Appl Microbiol Biotechnol; 2007 Jun; 75(3):499-514. PubMed ID: 17377788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diflomotecan. Ipsen.
    Osheroff N
    IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
    [No Abstract]   [Full Text] [Related]  

  • 16. New targets for non-small-cell lung cancer therapy.
    Alvarez M; Roman E; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors in cancer therapy.
    Fouladi M
    Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets.
    Mendoza FJ; Espino PS; Cann KL; Bristow N; McCrea K; Los M
    Arch Immunol Ther Exp (Warsz); 2005; 53(1):47-60. PubMed ID: 15761376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [[Inhibitors of histone deacetylase as new agents for prevention and treatment of cancer] ].
    Jung M
    Pharm Unserer Zeit; 2000 Nov; 29(6):385-8. PubMed ID: 11199916
    [No Abstract]   [Full Text] [Related]  

  • 20. American Association for Cancer Research 98th Annual Meeting. Anticancer agents - Part II.
    Filson S
    IDrugs; 2007 Jun; 10(6):359-61. PubMed ID: 17641994
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.